Phase Ib Study of Brigatinib Plus Bevacizumab in Patients With ALK-Rearranged Non-Small Cell Lung Cancer (NSCLC) Who Have Previously Progressed on Prior ALK-Directed Therapy
Latest Information Update: 06 Dec 2024
At a glance
- Drugs Bevacizumab (Primary) ; Brigatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 04 Dec 2024 Planned End Date changed from 1 Nov 2024 to 1 Jun 2025.
- 04 Dec 2024 Planned primary completion date changed from 1 Nov 2024 to 1 Jun 2025.
- 01 Apr 2024 Status changed from recruiting to active, no longer recruiting.